These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25200815)

  • 1. Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces.
    Myerson JW; He L; Allen JS; Williams T; Lanza G; Tollefsen D; Caruthers S; Wickline S
    Nanotechnology; 2014 Oct; 25(39):395101. PubMed ID: 25200815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis.
    Myerson J; He L; Lanza G; Tollefsen D; Wickline S
    J Thromb Haemost; 2011 Jul; 9(7):1292-300. PubMed ID: 21605330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis.
    Palekar RU; Myerson JW; Schlesinger PH; Sadler JE; Pan H; Wickline SA
    Mol Pharm; 2013 Nov; 10(11):4168-75. PubMed ID: 24063304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.
    Hanson SR; Harker LA
    Proc Natl Acad Sci U S A; 1988 May; 85(9):3184-8. PubMed ID: 3362867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile.
    Kaiser B; Richter M; Hauptmann J; Markwardt F
    Pharmazie; 1991 Feb; 46(2):128-31. PubMed ID: 1852761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis.
    Palekar RU; Jallouk AP; Myerson JW; Pan H; Wickline SA
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):446-55. PubMed ID: 26769047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.
    Palekar RU; Vemuri C; Marsh JN; Arif B; Wickline SA
    J Vasc Surg; 2016 Nov; 64(5):1459-1467. PubMed ID: 26482989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.
    Mehta AY; Mohammed BM; Martin EJ; Brophy DF; Gailani D; Desai UR
    J Thromb Haemost; 2016 Apr; 14(4):828-38. PubMed ID: 26748875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
    André P; LaRocca T; Delaney SM; Lin PH; Vincent D; Sinha U; Conley PB; Phillips DR
    Circulation; 2003 Nov; 108(21):2697-703. PubMed ID: 14597584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gold nanoparticles modified with self-assembled hybrid monolayer of triblock aptamers as a photoreversible anticoagulant.
    Huang SS; Wei SC; Chang HT; Lin HJ; Huang CC
    J Control Release; 2016 Jan; 221():9-17. PubMed ID: 26643617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
    Weitz JI; Hudoba M; Massel D; Maraganore J; Hirsh J
    J Clin Invest; 1990 Aug; 86(2):385-91. PubMed ID: 2384594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of antithrombotic activity of thrombin DNA aptamers by a murine thrombosis model.
    Zavyalova E; Samoylenkova N; Revishchin A; Golovin A; Pavlova G; Kopylov A
    PLoS One; 2014; 9(9):e107113. PubMed ID: 25192011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation.
    Li WX; Kaplan AV; Grant GW; Toole JJ; Leung LL
    Blood; 1994 Feb; 83(3):677-82. PubMed ID: 8298130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
    J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Prevention of Arterial Thrombosis with Albumin-Thrombin Inhibitor Conjugates.
    Marcos-Contreras OA; Myerson JW; Nong J; Brenner JS; Muzykantov VR; Glassman PM
    Mol Pharm; 2023 Nov; 20(11):5476-5485. PubMed ID: 37823223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
    Zhao B; Zhang Y; Huang Y; Yu J; Li Y; Wang Q; Ma Y; Song HY; Yu M; Mo W
    Thromb Haemost; 2017 Jan; 117(1):44-56. PubMed ID: 27904902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
    Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD
    Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
    McKenzie CR; Abendschein DR; Eisenberg PR
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1285-91. PubMed ID: 8857926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.